S. Meynier

发表

Role of PAR-4 in ovarian cancer

J. Tille, P. Ribaux, P. Petignat, 2015, Oncotarget.

A monocyte/dendritic cell molecular signature of SARS-CoV-2-related multisystem inflammatory syndrome in children with severe myocarditis

F. Rieux-Laucat, A. Fischer, J. Casanova, 2021, bioRxiv.

Type I interferon response and vascular alteration in chilblain‐like lesions during the COVID‐19 outbreak*

F. Rieux-Laucat, C. Delaugerre, D. Duffy, 2021, The British journal of dermatology.

Casitas B-lineage lymphoma Gene Mutation Ocular Phenotype

F. Rieux-Laucat, I. Meunier, C. Fardeau, 2022, International journal of molecular sciences.

After 95 years, it's time to eRASe JMML.

F. Rieux-Laucat, S. Meynier, 2020, Blood reviews.

FAS and RAS related Apoptosis defects: From autoimmunity to leukemia

F. Rieux-Laucat, S. Meynier, 2018, Immunological reviews.

NBEAL2 deficiency in humans leads to low CTLA-4 expression in activated conventional T cells

F. Rieux-Laucat, C. Picard, G. Leverger, 2023, Nature communications.

Circulating GRP78 antibodies from ovarian cancer patients: a promising tool for cancer cell targeting drug delivery system?

P. Ribaux, P. Petignat, Marie Cohen, 2017, Oncotarget.

In Ovo Progression of Borderline Ovarian Tumors

J. Tille, P. Petignat, Marie Cohen, 2017 .